KMG Fiduciary Partners LLC lowered its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 18.5% during the 2nd quarter, HoldingsChannel reports. The fund owned 63,078 shares of the company’s stock after selling 14,309 shares during the period. AbbVie accounts for approximately 1.5% of KMG Fiduciary Partners LLC’s portfolio, making the stock its 19th biggest holding. KMG Fiduciary Partners LLC’s holdings in AbbVie were worth $15,873,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also made changes to their positions in ABBV. Litman Gregory Wealth Management LLC purchased a new position in AbbVie during the fourth quarter valued at $28,000. Imprint Wealth LLC grew its stake in shares of AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after acquiring an additional 45 shares during the last quarter. Legacy Wealth Managment LLC ID grew its stake in shares of AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after acquiring an additional 73 shares during the last quarter. IFC & Insurance Marketing Inc. bought a new position in shares of AbbVie during the fourth quarter valued at $31,000. Finally, WestEnd Advisors LLC increased its holdings in shares of AbbVie by 160.4% during the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.
Wall Street Analysts Forecast Growth
ABBV has been the topic of a number of analyst reports. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. JPMorgan Chase & Co. raised their price objective on shares of AbbVie from $260.00 to $280.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Guggenheim upped their target price on shares of AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Finally, HSBC reiterated a “buy” rating and set a $300.00 price target on shares of AbbVie in a report on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $275.70.
AbbVie Stock Up 0.7%
Shares of NYSE ABBV opened at $247.86 on Tuesday. The firm’s 50-day moving average price is $242.67 and its 200-day moving average price is $225.28. The company has a market cap of $437.92 billion, a PE ratio of 70.02, a PEG ratio of 0.82 and a beta of 0.30. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47.
AbbVie (NYSE:ABBV – Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same period in the previous year, the business posted $2.97 earnings per share. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts anticipate that AbbVie Inc. will post 14.07 EPS for the current fiscal year.
AbbVie Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s payout ratio is 195.48%.
Key Stories Impacting AbbVie
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: Apogee acquisition strengthens immunology pipeline: AbbVie is set to acquire Apogee Therapeutics for approximately $10.9 billion, or $135.11 per share in cash. The deal adds zumilokibart, an investigational therapy for atopic dermatitis, asthma and other inflammatory diseases. Positive Phase 2 data support planned Phase 3 development, potentially helping AbbVie diversify its immunology portfolio and extend growth beyond existing products. The transaction is expected to close in the third quarter of 2026, subject to regulatory and shareholder approvals. AbbVie to Acquire Apogee Therapeutics for $10.9 Billion
- Positive Sentiment: Botox Cosmetic could gain a fifth indication: The FDA accepted AbbVie’s supplemental application for Botox Cosmetic to treat masseter muscle prominence, a jaw-muscle condition associated with a wider facial appearance. FDA acceptance does not guarantee approval, but a new aesthetic use could expand Botox’s addressable market and support growth in one of AbbVie’s best-known brands. AbbVie’s Botox Just Got A Step Closer To A Fifth Use
- Positive Sentiment: Analyst sentiment remains constructive: Brokerages maintain a consensus “Moderate Buy” rating, and commentary following second-quarter results characterized ABBV as a potentially undervalued dividend and growth opportunity. AbbVie Receives Consensus Rating of Moderate Buy
- Neutral Sentiment: Strong operating performance is balanced by valuation: AbbVie’s latest quarter exceeded EPS and revenue expectations, with revenue rising 10.2% year over year, driven by SKYRIZI, RINVOQ and neuroscience products. However, the stock’s elevated P/E ratio leaves less room for execution or regulatory disappointments. Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?
- Negative Sentiment: Execution and deal risks remain: The Apogee transaction requires approvals and could bring integration costs and development risk if zumilokibart fails to reproduce its Phase 2 results in larger trials. AbbVie must also manage ongoing biosimilar pressure and sustain growth from its core immunology products.
AbbVie Profile
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Read More
- Five stocks we like better than AbbVie
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
